Skip to main content
. 2022 Mar 10;2022:9226022. doi: 10.1155/2022/9226022

Figure 2.

Figure 2

Ligustrazine inhibits the expression of migration and adhesion-associated molecules in hypoxia-induced PMCs. (a) Western blot analysis of protein expression of migration and adhesion-associated molecules (VCAM-1 and ICAM-1) in hypoxia-induced PMCs treated with different concentrations of ligustrazine for 24 h. (b, c) qRT-PCR analysis of mRNA levels of migration and adhesion-associated molecules (VCAM-1 and ICAM-1) in hypoxia-induced PMCs treated with different concentrations of ligustrazine for 24 h. Compared with the control, ∗P < 0.05 and ∗∗P < 0.01. (d, e) FDA staining assay of cell viability in hypoxia-induced PMCs treated with different concentrations of ligustrazine for 24 h (200x). Compared with the control, ∗P < 0.05 and ∗∗P < 0.01. (f) MTT analysis of OD values in hypoxia-induced PMCs treated with different concentrations of ligustrazine for 24 h. Compared with the control, ∗P < 0.05 and ∗∗P < 0.01.